Showing 1259 results
-
Press release /The FDA's May 2019 approval of Zolgensma ®, a gene therapy for spinal muscular atrophy (SMA) in pediatric patients less than 2 years of age, marked an important milestone within the SMA community.…
-
Press release /Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1] Osteoporosis accounts for 8.9m bone fractures…
-
Press release /Chinese National Medical Products Administration (NMPA) approved Gilenya® for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older. Multiple sclerosis (MS) is…
-
Press release /Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +…
-
Press release /Chiffre d'affaires net des activités poursuivies[1] en hausse de 8% (tcc[2], +4% USD) soutenu par: Cosentyx: USD 858 millions, +25% (tcc) stimulé principalement par le maintien de la forte…
-
Press release /Der Nettoumsatz der fortzuführenden Geschäftsbereiche[1] steigt aufgrund folgender Beiträge um 8% (kWk[2], +4% USD): Cosentyx erzielt einen Umsatz von USD 858 Millionen (+25% kWk), vor allem dank…
-
Press release /FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from…
-
Press release /After review of clinical data from the Generation Program studies, the sponsors concluded that the potential benefit for participants taking CNP520 no longer outweighs the risk Basel, July 11…
-
Press release /Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1] More than 300,000 European men and women…
-
Press release /Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in secondary…